SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc. – RVNC
NEW YORK, NY / ACCESSWIRE / October 13, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ:RVNC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Revance and certain of its officers and/or directors have […]